In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage ...

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

Older adults with type 2 diabetes received fewer noninsulin diabetes medications in their final year of life, but insulin use ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Not surprisingly, the booming popularity of GLP-1 inhibitors left its mark as well. Scroll on to read our top 10 news of the year gone by, as well as our biggest feature stories, videos, opinion ...